Current Report Filing (8-k)
October 15 2021 - 2:38PM
Edgar (US Regulatory)
0001497130
false
0001497130
2021-10-14
2021-10-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 14, 2021
NANO
MOBILE HEALTHCARE, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
(State
or other jurisdiction
of incorporation)
|
000-55155
(Commission
File
Number)
|
98-0659770
(I.R.S.
Employer
Identification No.)
|
One
Boston Place Suite 2600
Boston, MA 02108
(Address of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (877) 626-6681
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
|
Common
Stock, par value of $0.00001
|
VNTH
|
OTCMKTS
|
Item
1.01. Entry into a Material Definitive Agreement
On
October 14, 2021, pursuant to an effective Settlement Agreement, for undisclosed amount,
the Company bought back the Convertible Notes that previous managements sold to VVIS
VIRES GROUP, INC. (“VVG”), a corporation formed and existing pursuant to the laws of the State of New York and having a principal
place of business located at 111 Great Neck Road, Suite 216, Great Neck, New York 11021.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of
Certain Officers.
On
October 14, 2021 Frank I Igwealor resigned as
a member of the Board of Directors (the "Board") of Nano Mobile Healthcare (the "Company"), effective as of the date
of such resignation. Mr. Igwealor also resigned as Chairman of the Board and Chief Executive
Officer of the Company effective as of such date. Mr. Igwealor's resignation was not the
result of any dispute or disagreement with the Company or the Company's Board of Directors on any matter relating to the operations,
policies or practices of the Company.
David
Noah Kittle has been appointed the President and CEO for the Company effective October 14, 2021.
|
|
Item 9.01.
|
Financial
Statements and Exhibits.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
NANO
MOBILE HEALTHCARE, INC.
|
Date: October 15, 2021
|
By:
/s/ David N Kittle
|
|
|
Name:
|
David N Kittle
|
|
|
Title:
|
President and CEO
|
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jan 2025 to Feb 2025
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Feb 2024 to Feb 2025
